文献速递外周动脉疾病

药物涂层球囊血管成形术与标准无涂层球囊血管成形术治疗长段股腘动脉病变的比较:AcoArt I 研究24个月结果的事后分析

Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
PubMed 文献 · Ann Vasc Surg · 2021-12-10

本研究基于AcoArt I研究,纳入病变长度≥15cm的患者87例(药物涂层球囊组42例,经皮腔内血管成形术组45例),比较24个月随访结果。药物涂层球囊组6个月晚期管腔丢失显著小于经皮腔内血管成形术组,24个月免于临床驱动的靶病变血运重建率和一期通畅率均显著更高,主要不良事件发生率无显著差异。

要点

  • 药物涂层球囊组6个月晚期管腔丢失0.27±0.90 mm,显著小于经皮腔内血管成形术组的1.32±0.91 mm(P<0.001)。
  • 24个月时药物涂层球囊组免于临床驱动的靶病变血运重建率81.58%,显著高于经皮腔内血管成形术组的43.18%(P<0.001)。
  • 24个月时药物涂层球囊组一期通畅率46.88%,显著高于经皮腔内血管成形术组的15.00%(P=0.003)。

核心结论

  • 在24个月随访期间,药物涂层球囊治疗长段股腘动脉病变的有效性优于标准无涂层球囊。
  • 药物涂层球囊的安全性不劣于经皮腔内血管成形术。

研究设计与样本

  • AcoArt I研究的事后分析,纳入经计算机断层血管造影或血管造影确认病变长度≥15cm的患者。
  • 根据治疗所用球囊导管将患者分为药物涂层球囊组和经皮腔内血管成形术组。
  • 共87例患者,药物涂层球囊组42例,经皮腔内血管成形术组45例。
  • 比较两组的人口学、病变和手术特征及24个月随访结果。
  • 主要疗效终点为6个月或临床驱动的靶病变血运重建时的血管造影晚期管腔丢失、一期通畅率、免于临床驱动的靶病变血运重建率以及24个月随访期间踝肱指数和Rutherford分级的改变。

主要发现

  • 两组人口学、病变和手术特征无显著差异。
  • 6个月随访血管造影显示药物涂层球囊组晚期管腔丢失为0.27±0.90 mm,显著小于经皮腔内血管成形术组的1.32±0.91 mm(P<0.001)。
  • 24个月时药物涂层球囊组免于临床驱动的靶病变血运重建率为81.58%,显著高于经皮腔内血管成形术组的43.18%(P<0.001)。
  • 24个月时药物涂层球囊组一期通畅率为46.88%,显著高于经皮腔内血管成形术组的15.00%(P=0.003)。
  • 药物涂层球囊组在6、12和24个月时踝肱指数均显著高于经皮腔内血管成形术组(P<0.001、P=0.004和P=0.018)。

关键数值与推荐

  • 药物涂层球囊组6个月踝肱指数显著高于经皮腔内血管成形术组(P<0.001),12个月(P=0.004),24个月(P=0.018)。
  • 药物涂层球囊组6个月和12个月Rutherford分级优于经皮腔内血管成形术组(P=0.033和P=0.012),24个月时两组Rutherford分级无显著差异(P=0.127)。

临床怎么用

  • 对于长段股腘动脉病变,药物涂层球囊在24个月随访中显示出优于标准无涂层球囊的有效性。
  • 药物涂层球囊的安全性等同于经皮腔内血管成形术。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Restenosis is a common complication after endovascular treatment of peripheral artery disease. Drug-coated balloon (DCB) treatment has been proven safe and effective in reducing the rate of restenosis for simple and short lesions. However, the clinical results of DCBs for long lesions are still very limited. This study aimed to evaluate the efficacy and safety of DCBs in the treatment of long femoropopliteal artery disease. And the results of this study will also complement the existing evidence of DCB treatment of long lesions. METHODS: Patients with lesion length ≥ 15cm according to computed tomography angiography (CTA) or angiography in the AcoArt I Study were included into this study. Based on the balloon catheter used in treatment, patients were divided into the DCB group and the percutaneous transluminal angioplasty (PTA) group. The demographic, lesion, and procedural characteristics and 24-month follow-up results were compared between the 2 groups. The primary efficacy endpoints were angiographic late lumen loss (LLL) at 6 months or at the time of clinically driven target lesion revascularization (CD-TLR), primary patency (PP), freedom from CD-TLR, and changes in the ankle-brachial index (ABI) and Rutherford class during 24 months of follow-up. The safety endpoint was the occurrence of major adverse events. RESULTS: The total number of patients was 87, including 42 in the DCB group and 45 in the PTA group. There were no significant differences between the 2 groups in demographic, lesion,and procedural characteristics. The 6-month follow-up angiography showed that the LLL was significantly smaller in the DCB group than the PTA group (0.27 ± 0.90 mm vs 1.32 ± 0.91 mm; P < 0.001). At 24 months, compared with the PTA group, the DCB group had a significantly higher rate of freedom from CD-TLR (81.58% vs 43.18%; P < 0.001) and a significantly higher PP rate (46.88% vs 15.00%; P = 0.003). The DCB group had a significantly higher ABI than the PTA group at 6, 12, and 24 months (P < 0.001, P = 0.004 and P = 0.018, respectively). The DCB group had a better Rutherford class than the PTA group at 6 and 12 months (P = 0.033 and P = 0.012, respectively); the Rutherford class did not significantly differ between the 2 groups at 24 months (P = 0.127). The incidence of major adverse events did not significantly differ between the 2 groups. CONCLUSION: The effectiveness of the DCB is superior to a standard uncoated balloon in treating long lesions during 24 months of follow-up. Furthermore, the safety of the DCB is equivalent to that of PTA.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Jia S, Liu J, Sun G, et al. Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study. Ann Vasc Surg. 2021. PMID: 34902474. doi:10.1016/j.avsg.2021.10.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。